# Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs

* Alzamend Neuro tackles Alzheimer’s, BD, MDD and PTSD with breakthrough therapies.
* AL001 delivers improved brain targeting and fewer side effects than lithium carbonate.
* Phase II trials underway with support from Mass General and AI partner QMENTA.
* ALZN002 offers a novel, adjuvant-free immunotherapy for Alzheimer’s disease.

 Alzamend Neuro (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company tackling some of the most pressing neurological and psychiatric conditions of our time — including Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to “Make Alzheimer’s Just a Memory,” the Atlanta-based company is advancing a robust pipeline of therapies aimed at delivering long-overdue innovation in safety, efficacy, and tolerability. Rather than tweaking existing treatments, Alzamend is engineering bold new approaches that directly address the limitations of current standards of care.

 Leading its portfolio is AL001, a patented ionic cocrystal formulation of lithium designed to penetrate the brain more effectively while reducing systemic side effects. In partnership with Massachusetts General Hospital and imaging partner QMENTA, the company launched the first of five Phase II trials in…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to ALZN are available in the company’s newsroom at https://ibn.fm/ALZN

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/alzamend-neuro-inc-nasdaq-alzn-targets-transformative-mental-health-breakthroughs/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/alzamend-neuro-advances-breakthrough-therapies-for-neurological-and-psychiatric-conditions/cc699220db9d7a5096d0d6bcff834a7a) 

 



[Reddit Post](https://www.reddit.com/r/technology_press/comments/1kydljt/alzamend_neuro_advances_breakthrough_therapies/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/29/hintJGCN.webp)